8-K: Tevogen Bio Holdings Issues Series A and B Preferred Stock, Secures $8 Million Investment

Tevogen Bio Holdings Inc. has filed certificates of designation for Series A and B preferred stock, securing an $8 million investment and addressing prior liabilities.

Summary

• Tevogen Bio Holdings Inc. has created and issued Series A and B Preferred Stock.
• The Series A Preferred Stock was created through a securities purchase agreement with an existing investor, Dr. Manmohan Patel, who agreed to purchase $8 million of these shares.
• The Series B Preferred Stock was created to address approximately $3.6 million in liabilities and obligations assumed from Semper Paratus Acquisition Corporation's sponsor.
• The Series A Preferred Stock ranks senior to common stock and Series B Preferred Stock regarding dividends and liquidation rights.
• Series A Preferred Stock holders are entitled to a 5% annual cumulative dividend, increasing by 2% each year, and also participate in common stock dividends on an as-converted basis.
• The Series A Preferred Stock can be converted into common stock at a conversion price of $4.00 per share, subject to adjustments.
• The Series B Preferred Stock ranks junior to Series A Preferred Stock but senior to common stock and other equity securities, except for Series A and B Preferred Stock.
• Series B Preferred Stock holders receive quarterly dividends starting at 3.25%, increasing by 0.25% monthly, capped at 7.5% per quarter.
• Dividends on Series B Preferred Stock are paid to creditors of the assumed liabilities until those liabilities are settled.
• The Series A Preferred Stock has a liquidation preference equal to the original issue price plus accrued dividends or the amount payable if converted to common stock, whichever is greater.
• The Series B Preferred Stock has a liquidation preference equal to the aggregate amount of the liabilities assumed by the sponsor.
• The company has the right to call the Series A Preferred Stock at $4,000 per share plus accrued dividends if the common stock price exceeds $5.00 for 20 days and a resale registration is effective.
• The company can call the Series B Preferred Stock at the issue price of $1,000 per share.

Sentiment

Score: 7

Explanation: The document indicates a positive development for the company as it secures funding and addresses liabilities. However, the terms of the preferred stock, particularly the call options, introduce some limitations for investors.

Positives

• The company secured an $8 million investment through the issuance of Series A Preferred Stock.
• The issuance of Series B Preferred Stock addresses approximately $3.6 million in liabilities.
• The Series A Preferred Stock has a cumulative dividend feature, providing a consistent return to investors.
• The Series A Preferred Stock has a conversion option, allowing investors to participate in potential common stock appreciation.
• The Series B Preferred Stock provides a structured approach to paying down assumed liabilities.

Negatives

• The Series A Preferred Stock has a call option, which could limit potential upside for investors if the company chooses to redeem the shares.
• The Series B Preferred Stock dividends are initially used to pay down assumed liabilities, which may not directly benefit the holders until those liabilities are settled.
• The Series B Preferred Stock is not convertible into common stock, limiting potential upside for investors.

Risks

• The company's ability to call the Series A Preferred Stock could limit potential gains for investors if the common stock price increases significantly.
• The Series B Preferred Stock dividends are contingent on the company's ability to pay and are initially directed towards settling assumed liabilities.
• The conversion price of the Series A Preferred Stock is subject to adjustments, which could impact the number of common shares received upon conversion.
• The company's financial performance will impact its ability to pay dividends and redeem the preferred stock.

Future Outlook

The company has established the terms for the Series A and B Preferred Stock, which will impact its capital structure and financial obligations going forward. The company may call the Series A and B preferred stock under certain conditions.

Management Comments

• The document is a formal filing and does not contain direct quotes from management.

Industry Context

The issuance of preferred stock is a common method for companies to raise capital and manage liabilities. This move allows Tevogen Bio to secure funding and address obligations, which is typical for companies in the biotechnology sector.

Comparison to Industry Standards

• The terms of the Series A Preferred Stock, including the dividend rate and conversion price, are within the range of similar financings in the biotech industry.
• The use of preferred stock to address liabilities, as seen with the Series B Preferred Stock, is a common strategy for companies undergoing restructuring or mergers.
• The call options on both series of preferred stock are standard features that allow the company to manage its capital structure.
• Companies like Moderna and BioNTech have also used preferred stock offerings to raise capital, although the specific terms vary based on the company's stage and financial situation.

Related Party Transactions

• The Series A Preferred Stock was issued to Dr. Manmohan Patel, an existing investor and beneficial owner of more than 5% of the company's common stock.
• The Series B Preferred Stock was issued to the sponsor of Semper Paratus Acquisition Corporation, a beneficial owner of more than 5% of the company's common stock.

Stakeholder Impact

• Shareholders will see a change in the company's capital structure with the introduction of preferred stock.
• The company's creditors will be impacted by the payment of dividends on the Series B Preferred Stock, which are initially directed towards settling assumed liabilities.
• The company's employees may be indirectly impacted by the financial stability provided by the capital raise and liability management.

Next Steps

• The company will manage the dividend payments and potential redemption of the Series A and B Preferred Stock.
• The company will monitor the common stock price to determine if the call option for the Series A Preferred Stock can be exercised.
• The company will continue to work towards settling the liabilities associated with the Series B Preferred Stock.

Key Dates

Keywords

Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, Investment, Dividends, Conversion Rights, Liquidation Preference, Redemption, Capital Raise, Tevogen Bio Holdings